| 2025 |
PCMT1 promotes formation of C-terminal cyclic imide modifications on C-terminal asparagine residues of CRBN (cereblon) substrates, co-regulating levels of metabolic enzymes glutamine synthetase (GLUL) and inorganic pyrophosphatase 1 (PPA1) in vitro, in cells, and in vivo; this regulation is associated with the proepileptic phenotype of CRBN knockout mouse models. |
In vitro biochemical assays, cell-based experiments, in vivo mouse models, CRBN knockout phenotype analysis |
Nature chemical biology |
High |
40196534 41461925
|
| 2025 |
PCMT1 is unconventionally secreted and enzymatically interacts with the ectodomain of TGF-β receptor 2 (TGFBR2), reversing N63 deamidation (isoaspartate formation) on TGFBR2, which triggers TGFBR2 ubiquitination and degradation, thereby suppressing TGF-β1/Smad signaling and inhibiting kidney fibrosis. |
Immunoprecipitation, gene lentivirus overexpression/knockout, post-translational modification mass spectrometry, tubule-specific Pcmt1 knockout murine models |
Journal of the American Society of Nephrology : JASN |
High |
40036072
|
| 2022 |
PCMT1 is released extracellularly from ovarian cancer cells and interacts with the ECM protein LAMB3, which binds to integrin and activates FAK-Src signaling to promote cancer cell migration, adhesion, and metastasis. |
Immunoprecipitation followed by mass spectrometry (IP-MS), CRISPR/Cas9 knockout screen, western blot, live cell imaging, in vivo mouse models |
Journal of experimental & clinical cancer research : CR |
High |
35033172
|
| 2014 |
PCMT1 methylates histone H4 at aspartate 24 (H4D24me), acting as a novel histone methyltransferase involved in protein repair of isoaspartate-containing histones; the H4D24me mark is specifically recognized by VprBP (a chromo domain-containing protein), potentially implicating H4D24me in H4 degradation and histone homeostasis. |
In vitro methyltransferase assay, generation of H4D24me-specific antibodies, in vivo chromatin analysis in mouse and human cells |
Scientific reports |
High |
25327473
|
| 2017 |
PCMT1 inhibits neuronal apoptosis after subarachnoid hemorrhage by reducing MST1 phosphorylation and levels of cleaved MST1 (cl-MST1); pharmacological activation of PCMT1 with CGP 3466B reduced MST1 activity and apoptosis, while acceleration of MST1 phosphorylation (calyculin A) or increase in cl-MST1 (chelerythrine) reversed these neuroprotective effects. |
Rat SAH model, pharmacological agonist/antagonist administration, western blotting, immunofluorescence, intracerebroventricular drug delivery |
Translational stroke research |
Medium |
28534197
|
| 2020 |
Protein kinase C theta (PKCθ) modulates PCMT1 expression through hnRNPL in induced regulatory T cells; PCMT1 acts as an instability factor by methylating the FOXP3 promoter, destabilizing FOXP3 expression. |
Cell-penetrating peptide mimic delivery of anti-PKCθ, RNA processing analysis, cell-penetrating antibody targeting PCMT1, T cell differentiation assays |
Molecular therapy : the journal of the American Society of Gene Therapy |
Medium |
32592691
|
| 2012 |
Pcmt1-deficient mice accumulate isomerized aspartyl residues, have constitutively activated insulin signaling in the brain (elevated phospho-Akt, PDK1, mTOR), and show 20-30% brain enlargement leading to fatal seizures; wortmannin (PI3K inhibitor) reduced brain size toward wild-type and nearly doubled lifespan in Pcmt1-/- animals. |
Pcmt1 knockout mouse model, oral wortmannin administration, immunoblotting for phospho-Akt/PDK1/mTOR, brain size measurement, lifespan analysis |
PloS one |
High |
23071621
|
| 2026 |
LITAF interacts with PCMT1 and promotes ubiquitination-mediated degradation of PCMT1, thereby inhibiting COX-2-mediated arachidonic acid metabolism and enhancing sensitivity of breast cancer cells to paclitaxel. |
Co-immunoprecipitation (Co-IP), ubiquitination assay, western blot, in vivo nude mouse model, metabolomics |
Frontiers in pharmacology |
Medium |
42051267
|
| 2026 |
The deubiquitinating enzyme USP13 directly interacts with PCMT1 and removes polyubiquitination of PCMT1 to maintain its stability, promoting prostate cancer cell proliferation and enzalutamide resistance. |
Co-immunoprecipitation, ubiquitination assay, USP13 silencing in vitro and in vivo, prostate cancer cell and xenograft models |
Cell death & disease |
Medium |
42056074
|
| 2025 |
Multi-omics analysis of Pcmt1 knockout mice revealed that PCMT1 substrates (isoaspartate-carrying proteins) accumulate predominantly in extracellular and membrane-related compartments; overexpressed PCMT1 interacts with proteins mainly in extracellular and membrane-related categories, indicating an extracellular repair function beyond its canonical intracellular role. |
isoD-proteomics, global proteomics, transcriptomics in Pcmt1 KO vs WT mice; proteomic analysis of PCMT1-overexpressing cells |
Journal of proteome research |
Medium |
40287848
|
| 2014 |
hsa-miR-195 directly targets the PCMT1 3'UTR as validated by co-transfection of pmirGLO-PCMT1 and pEGP-miR-195 in a luciferase reporter assay, significantly decreasing PCMT1 expression. |
Dual luciferase reporter assay (pmirGLO-PCMT1 + pEGP-miR-195 co-transfection) |
Tumour biology |
Medium |
25119594
|
| 2023 |
PCMT1 regulates migration, invasion, and apoptosis of prostate cancer cells by modulating the PI3K/AKT/GSK-3β signaling pathway, as demonstrated by PCMT1 overexpression and knockdown experiments in vitro and in vivo. |
PCMT1 overexpression and knockdown in prostate cancer cell lines, in vivo xenograft model, western blot for PI3K/AKT/GSK-3β pathway components |
Aging |
Low |
37899170
|
| 2023 |
PCMT1 knockdown in triple-negative breast cancer MDA-MB-231 cells globally altered transcriptome profiles including 1,084 differentially expressed genes enriched in immune/inflammation and cell adhesion pathways, and 2,287 regulated alternative splicing events enriched in cell cycle pathways; 34 RNA binding protein genes were dysregulated. |
shRNA knockdown, RNA-seq transcriptome analysis, RT-PCR validation |
PeerJ |
Low |
37953789
|